Piper Jaffray is out with its report on Boston Scientific BSX, previewing Q4 10 earnings before they are announced this evening.
In a note to clients, Piper Jaffray writes, "Barring a major miss relative to expectations, we think Q4 results are largely academic with the focus largely on the company's 2011 outlook.We expect Boston to finish 2010 with proforma Q4 EPS of $0.17 and full year 2010 EPS of $0.65. We estimate 2011 revenue at $7,705MM, down 1% Y/Y on a reported basis."
Piper Jaffray maintains Neutral and a $7 PT on BSX.
Shares of BSX closed Monday at $6.98, down 0.14% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst Ratingsboston scientificHealth CareHealth Care EquipmentPiper Jaffray
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in